Mohamed A. Elblbesy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohamed A. Elblbesy has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Bothaina A. Kandil
Department of Radiological Science and Medical Imaging, Faculty of Allied Medical Science, Pharos University, Alexandria 21311, Egypt
1 shared publication- Bothaina A. Kandil
Department of Radiological Science and Medical Imaging, Faculty of Allied Medical Science, Pharos University, Alexandria 21311, Egypt
1 shared publication - Ghareb Mohamed Soliman
Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia
1 shared publication - Mohamed A. Safwat
Department of Pharmaceutics, Faculty of Pharmacy, South Valley University, Qena 83523, Egypt
1 shared publication - Nermin E. Eleraky
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Biophysics
- Vol. 11 (2) , 121-129
Hemorheological measurements over the shear-thinning regime. In vitro comparative study for hyperglycemia
We investigated the shear thinning of normal and diabetic blood experimentally. The shear thinning of the blood has been analyzed using the Power-law model. Over the viscosity time course, the coagulation process of blood samples from diabetic and healthy subjects was observed. The shear thinning behavior of blood samples was examined in the shear rate ranging from 5 s−1 to 222 s−1, and viscosity time-course was studied at a shear rate of 50 s−1. The consistency coefficients were 8.638 ± 0.4860 mPa·s, and 6.658 ± 0.3219 mPa·s for diabetic blood and control, respectively. This difference was statistically significant (p < 0.0001). The parameters extracted from the viscosity–time curve were the time-to-gel point (TGP), maximum clot viscosity (MCV), and final clot viscosity (FCV). The diabetic blood exhibited a significantly high (p < 0.0001) shorter TGP (148.8 ± 6.024 s) than control (199.1 ± 4.865 s). A considerably higher MCV for diabetic blood (26.39 ± 1.451 cP) than the control (17.54 ± 2.324 cP) was reported. FCV for diabetic blood (10.89 ± 1.12 cP) was significantly higher than control (7.6 ± 0.8 cP). The viscosity time course as well as features obtained via the power-law model reflected the flow state of diabetic blood.
- 1 January 2024
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Biophysics
- Vol. 11 (2) , 121-129
Open AccessHemorheological measurements over the shear-thinning regime. In vitro comparative study for hyperglycemia
We investigated the shear thinning of normal and diabetic blood experimentally. The shear thinning of the blood has been analyzed using the Power-law model. Over the viscosity time course, the coagulation process of blood samples from diabetic and healthy subjects was observed. The shear thinning behavior of blood samples was examined in the shear rate ranging from 5 s−1 to 222 s−1, and viscosity time-course was studied at a shear rate of 50 s−1. The consistency coefficients were 8.638 ± 0.4860 mPa·s, and 6.658 ± 0.3219 mPa·s for diabetic blood and control, respectively. This difference was statistically significant (p < 0.0001). The parameters extracted from the viscosity–time curve were the time-to-gel point (TGP), maximum clot viscosity (MCV), and final clot viscosity (FCV). The diabetic blood exhibited a significantly high (p < 0.0001) shorter TGP (148.8 ± 6.024 s) than control (199.1 ± 4.865 s). A considerably higher MCV for diabetic blood (26.39 ± 1.451 cP) than the control (17.54 ± 2.324 cP) was reported. FCV for diabetic blood (10.89 ± 1.12 cP) was significantly higher than control (7.6 ± 0.8 cP). The viscosity time course as well as features obtained via the power-law model reflected the flow state of diabetic blood.
- Open Access
- 1 January 2021
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Biophysics
- Vol. 8 (1) , 57-65
The refractive index of human blood measured at the visible spectral region by single-fiber reflectance spectroscopy
The refractive index is an essential biophysical parameter used in many diagnostic and therapeutic biomedical applications. In the present study, the refractive index of control and anemic blood was measured using the total internal reflection fiber optics technique. For control, the refractive index measured by the indicated method was significantly higher than anemic blood over the wavelengths in the visible spectral region used in this study. Strong linear correlations between refractive index and hemoglobin concentration were obtained for control and anemic blood. These findings could enhance the use of the refractive index in many applications of blood analysis and hematology.
- 1 January 2021
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Biophysics
- Vol. 8 (1) , 57-65
Open AccessThe refractive index of human blood measured at the visible spectral region by single-fiber reflectance spectroscopy
The refractive index is an essential biophysical parameter used in many diagnostic and therapeutic biomedical applications. In the present study, the refractive index of control and anemic blood was measured using the total internal reflection fiber optics technique. For control, the refractive index measured by the indicated method was significantly higher than anemic blood over the wavelengths in the visible spectral region used in this study. Strong linear correlations between refractive index and hemoglobin concentration were obtained for control and anemic blood. These findings could enhance the use of the refractive index in many applications of blood analysis and hematology.
- Open Access
- 18 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 254
Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice
Epigallocatechin-3-gallate (EGCG) is a pleiotropic compound with anticancer, anti-inflammatory, and antioxidant properties. To enhance EGCG anticancer efficacy, it was loaded onto gold nanoparticles (GNPs). EGCG-GNPs were prepared by a simple green synthesis method and were evaluated using different techniques. Hemocompatibility with human blood and in vivo anticancer efficacy in Ehrlich ascites carcinoma-bearing mice were evaluated. EGCG/gold chloride molar ratio had a marked effect on the formation and properties of EGCG-GNPs where well-dispersed spherical nanoparticles were obtained at a molar ratio not more than 0.8:1. The particle size ranged from ~26 to 610 nm. High drug encapsulation efficiency and loading capacity of ~93 and 32%, respectively were obtained. When stored at 4 °C for three months, EGCG-GNPs maintained over 90% of their drug payload and had small changes in their size and zeta potential. They were non-hemolytic and had no deleterious effects on partial thromboplastin time, prothrombin time, and complement protein C3 concentration. EGCG-GNPs had significantly better in vivo anticancer efficacy compared with pristine EGCG as evidenced by smaller tumor volume and weight and higher mice body weight. These results confirm that EGCG-GNPs could serve as an efficient delivery system for EGCG with a good potential to enhance its anticancer efficacy.
- 18 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 254
Open AccessEpigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice
Epigallocatechin-3-gallate (EGCG) is a pleiotropic compound with anticancer, anti-inflammatory, and antioxidant properties. To enhance EGCG anticancer efficacy, it was loaded onto gold nanoparticles (GNPs). EGCG-GNPs were prepared by a simple green synthesis method and were evaluated using different techniques. Hemocompatibility with human blood and in vivo anticancer efficacy in Ehrlich ascites carcinoma-bearing mice were evaluated. EGCG/gold chloride molar ratio had a marked effect on the formation and properties of EGCG-GNPs where well-dispersed spherical nanoparticles were obtained at a molar ratio not more than 0.8:1. The particle size ranged from ~26 to 610 nm. High drug encapsulation efficiency and loading capacity of ~93 and 32%, respectively were obtained. When stored at 4 °C for three months, EGCG-GNPs maintained over 90% of their drug payload and had small changes in their size and zeta potential. They were non-hemolytic and had no deleterious effects on partial thromboplastin time, prothrombin time, and complement protein C3 concentration. EGCG-GNPs had significantly better in vivo anticancer efficacy compared with pristine EGCG as evidenced by smaller tumor volume and weight and higher mice body weight. These results confirm that EGCG-GNPs could serve as an efficient delivery system for EGCG with a good potential to enhance its anticancer efficacy.